LAL enzyme activity analysis could be included in this test series, and although liver biopsy is not widespread, clinical guidelines also recommend performing this investigation to establish the diagnosis of NAFLD and to assess the degree of fibrosis. This evidence concerns the gene LIPA and metabolic dysfunction-associated steatotic liver disease.